Literature DB >> 19506189

An objective evaluation of eyedrop instillation in patients with glaucoma.

Jennifer L Stone1, Alan L Robin, Gary D Novack, David W Covert, Gerald D Cagle.   

Abstract

OBJECTIVES: To evaluate the performance of patients with ocular hypertension and glaucoma who are experienced in the instillation of topical ocular hypotensive medications.
METHODS: We conducted a prospective, open-label study at a single private practice site. We enrolled 139 patients with a diagnosis of glaucoma or ocular hypertension who used 1 or more topical ocular hypotensive medications for at least 6 months and who instilled their own medications. Patients were questioned regarding their use of topical ocular hypotensive medications, and we used a video recording to evaluate patient performance of eyedrop instillation with 2 bottle designs.
RESULTS: Patients reported relatively good performance on eyedrop instillation. One hundred twenty-nine of 139 patients (92.8%) reported no problem putting in their eyedrops, and 86 of 139 (61.9%) believed that they never missed their eye when administering the drops. The proportions of patients who were able to instill a single drop into the eye without touching the bottle to the eye were 14 of 64 (21.9%) with a 15-mL bottle and 36 of 117 (30.8%) with a 2.5-mL bottle.
CONCLUSIONS: Under a single direct observation, patients experienced in the use of topical ocular hypotensive agents performed relatively poorly when instilling a single eyedrop into the eye without touching the bottle tip to the eye or the ocular adnexae. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00522600.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19506189     DOI: 10.1001/archophthalmol.2009.96

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  53 in total

1.  Patterns of Glaucoma Medication Adherence over Four Years of Follow-Up.

Authors:  Paula Anne Newman-Casey; Taylor Blachley; Paul P Lee; Michele Heisler; Karen B Farris; Joshua D Stein
Journal:  Ophthalmology       Date:  2015-08-25       Impact factor: 12.079

2.  The influence of health literacy level on an educational intervention to improve glaucoma medication adherence.

Authors:  Kelly W Muir; Alice Ventura; Sandra S Stinnett; Abraham Enfiedjian; R Rand Allingham; Paul P Lee
Journal:  Patient Educ Couns       Date:  2011-10-13

3.  Safeguarding the process of drug administration with an emphasis on electronic support tools.

Authors:  Hanna M Seidling; Anette Lampert; Kristina Lohmann; Julia T Schiele; Alexander J F Send; Diana Witticke; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

4.  A Glaucoma-Specific Brief Motivational Interviewing Training Program for Ophthalmology Para-professionals: Assessment of Feasibility and Initial Patient Impact.

Authors:  Paula Anne Newman-Casey; Olivia Killeen; Sarah Miller; Chamisa MacKenzie; Leslie M Niziol; Ken Resnicow; John W Creswell; Paul Cook; Michele Heisler
Journal:  Health Commun       Date:  2018-12-20

5.  Provider use of collaborative goal setting with glaucoma patients.

Authors:  Betsy Sleath; Catherine Slota; Susan J Blalock; Robyn Sayner; Delesha M Carpenter; Kelly W Muir; Mary Elizabeth Hartnett; Alan L Robin
Journal:  Optom Vis Sci       Date:  2014-05       Impact factor: 1.973

6.  Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops.

Authors:  Tina T Wong; Gary D Novack; Jayaganesh V Natarajan; Ching Lin Ho; Hla M Htoon; Subbu S Venkatraman
Journal:  Drug Deliv Transl Res       Date:  2014-08       Impact factor: 4.617

7.  Development of a novel bioerodible dexamethasone implant for uveitis and postoperative cataract inflammation.

Authors:  Srinivas Rao Chennamaneni; Christina Mamalis; Bonnie Archer; Zack Oakey; Balamurali K Ambati
Journal:  J Control Release       Date:  2013-01-13       Impact factor: 9.776

8.  First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results.

Authors:  Jordana K Schmier; David W Covert
Journal:  Clin Ophthalmol       Date:  2010-05-14

9.  Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy.

Authors:  Gregory Reardon; Gail F Schwartz; Sameer Kotak
Journal:  BMC Ophthalmol       Date:  2010-03-02       Impact factor: 2.209

10.  First-year treatment costs among new initiators of topical prostaglandin analogs.

Authors:  Jordana K Schmier; David W Covert; Alan L Robin
Journal:  Clin Ophthalmol       Date:  2009-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.